This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Kathleen Colleran, University of New Mexico
ClinicalTrials.gov Identifier:
NCT00656331
First received: April 7, 2008
Last updated: April 11, 2012
Last verified: April 2012
  Purpose
The purpose of this study is to compare the effects of the cholesterol medication taken with each blood pressure medication alone on heart disease risk factors including blood pressure, cholesterol, inflammation, blood sugar control, blood vessal function, and other heart disease risk factors.

Condition Intervention
Hypertension Drug: Amlodipine and Hydrocholorothiazide

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications: A Comparison of Amlodipine and Hydrochlorothiazide

Resource links provided by NLM:


Further study details as provided by Kathleen Colleran, University of New Mexico:

Primary Outcome Measures:
  • PAI-1 [ Time Frame: study completion ]

Estimated Enrollment: 20
Study Start Date: August 2005
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Amlodipine
Drug: Amlodipine and Hydrocholorothiazide
Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
Active Comparator: 2
HCTZ
Drug: Amlodipine and Hydrocholorothiazide
Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • mild hypertension and high cholesterol

Exclusion Criteria:

  • diabetes and heart disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00656331

Locations
United States, New Mexico
UNMHSC
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Investigators
Principal Investigator: Kathleen Colleran, MD University of New Mexico
  More Information

Responsible Party: Kathleen Colleran, Professor of Medicine, University of New Mexico
ClinicalTrials.gov Identifier: NCT00656331     History of Changes
Other Study ID Numbers: 05-106
Study First Received: April 7, 2008
Last Updated: April 11, 2012

Additional relevant MeSH terms:
Atorvastatin Calcium
Amlodipine
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Vasodilator Agents

ClinicalTrials.gov processed this record on June 23, 2017